188 related articles for article (PubMed ID: 25270279)
1. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb.
Gruia F; Du J; Santacroce PV; Remmele RL; Bee JS
J Pharm Sci; 2015 Apr; 104(4):1539-42. PubMed ID: 25270279
[TBL] [Abstract][Full Text] [Related]
2. Technical decision making with higher order structure data: higher order structure characterization during protein therapeutic candidate screening.
Jiang Y; Li C; Li J; Gabrielson JP; Wen J
J Pharm Sci; 2015 Apr; 104(4):1533-8. PubMed ID: 25716705
[TBL] [Abstract][Full Text] [Related]
3. Technical decision-making with higher order structure data: specific binding of a nonionic detergent perturbs higher order structure of a therapeutic monoclonal antibody.
Budyak IL; Doyle BL; Weiss WF
J Pharm Sci; 2015 Apr; 104(4):1543-7. PubMed ID: 25545760
[TBL] [Abstract][Full Text] [Related]
4. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation.
Arthur KK; Dinh N; Gabrielson JP
J Pharm Sci; 2015 Apr; 104(4):1548-54. PubMed ID: 25561411
[TBL] [Abstract][Full Text] [Related]
5. Self-buffering antibody formulations.
Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
[TBL] [Abstract][Full Text] [Related]
6. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
[TBL] [Abstract][Full Text] [Related]
7. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
8. Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies.
Thakkar SV; Joshi SB; Jones ME; Sathish HA; Bishop SM; Volkin DB; Middaugh CR
J Pharm Sci; 2012 Sep; 101(9):3062-77. PubMed ID: 22581714
[TBL] [Abstract][Full Text] [Related]
9. A critical evaluation of Tm(FTIR) measurements of high-concentration IgG1 antibody formulations as a formulation development tool.
Matheus S; Mahler HC; Friess W
Pharm Res; 2006 Jul; 23(7):1617-27. PubMed ID: 16783474
[TBL] [Abstract][Full Text] [Related]
10. Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics.
Joshi V; Shivach T; Yadav N; Rathore AS
Anal Chem; 2014 Dec; 86(23):11606-13. PubMed ID: 25350583
[TBL] [Abstract][Full Text] [Related]
11. Experimental Model System to Study pH Shift-Induced Aggregation of Monoclonal Antibodies Under Controlled Conditions.
Oyetayo OO; Kiefer H
Pharm Res; 2016 Jun; 33(6):1359-69. PubMed ID: 26928669
[TBL] [Abstract][Full Text] [Related]
12. Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications.
Bahrenburg S; Karow AR; Garidel P
Biotechnol J; 2015 Apr; 10(4):610-22. PubMed ID: 25641961
[TBL] [Abstract][Full Text] [Related]
13. Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage.
Svilenov HL; Kulakova A; Zalar M; Golovanov AP; Harris P; Winter G
J Pharm Sci; 2020 Jan; 109(1):584-594. PubMed ID: 31689429
[TBL] [Abstract][Full Text] [Related]
14. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody.
Wakankar AA; Liu J; Vandervelde D; Wang YJ; Shire SJ; Borchardt RT
J Pharm Sci; 2007 Jul; 96(7):1708-18. PubMed ID: 17238195
[TBL] [Abstract][Full Text] [Related]
15. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
Brummitt RK; Nesta DP; Roberts CJ
J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
[TBL] [Abstract][Full Text] [Related]
16. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
17. Technical Decision Making With Higher Order Structure Data: Perspectives on Higher Order Structure Characterization From the Biopharmaceutical Industry.
Weiss WF; Gabrielson JP; Al-Azzam W; Chen G; Davis DL; Das TK; Hayes DB; Houde D; Singh SK
J Pharm Sci; 2016 Dec; 105(12):3465-3470. PubMed ID: 27743675
[TBL] [Abstract][Full Text] [Related]
18. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics.
Depaz RA; Chevolleau T; Jouffray S; Narwal R; Dimitrova MN
J Pharm Sci; 2014 May; 103(5):1384-93. PubMed ID: 24643773
[TBL] [Abstract][Full Text] [Related]
19. Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody.
Baek Y; Singh N; Arunkumar A; Zydney AL
Pharm Res; 2017 Mar; 34(3):629-639. PubMed ID: 28035628
[TBL] [Abstract][Full Text] [Related]
20. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity.
Rizzo JM; Shi S; Li Y; Semple A; Esposito JJ; Yu S; Richardson D; Antochshuk V; Shameem M
J Pharm Sci; 2015 May; 104(5):1632-40. PubMed ID: 25757872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
